How to Evaluate a HealthTech Startup at Series A: Investor Framework
US healthcare is a $4.5T market with systemic inefficiencies. Digital health adoption was permanently accelerated by COVID-19 telehealth waivers. High barriers to entry create durable moats. This guide covers a 7-step evaluation framework specifically designed for HealthTech startups at the Series A stage.
7-Step Evaluation Framework: HealthTech at Series A
Verify the Founding Team
For HealthTech startups, the team is the primary investment signal at early stage. Check: (1) domain expertise in HealthTech — does the team have direct experience in the industry they're disrupting? (2) prior startup experience and exits; (3) LinkedIn verification of claimed roles and credentials; (4) GitHub activity for technical founders; (5) reference calls with former colleagues or investors.
Validate Traction Metrics
The most important metric for HealthTech at this stage is Clinical Outcome Improvement. Benchmark: Must demonstrate statistically significant improvement vs. standard of care. The most defensible moat in healthtech. Always request underlying data — bank statements, CRM exports, or platform data — rather than trusting deck figures alone.
Screen for Sector-Specific Red Flags
HealthTech pitch decks frequently contain these critical red flags that general DD frameworks miss: FDA clearance not secured for medical device or diagnostic claims (CRITICAL): Any product that makes diagnostic or treatment claims requires FDA 510(k) clearance or De Novo authorization. Selling without clearance is illegal and investor-threatening.. No HIPAA Business Associate Agreement (BAA) template (CRITICAL): Any company handling Protected Health Information (PHI) must execute BAAs with covered entities. Absence signals regulatory immaturity.. Clinical claims without peer-reviewed evidence (HIGH): Healthtech companies that claim clinical superiority without published studies or rigorous data will face regulatory and payor scrutiny that stalls commercialization.
Validate Market Size Independently
The HealthTech market is $500B+ (digital health globally by 2030), growing at 28% CAGR through 2030. Validate TAM sourcing: is it bottom-up or top-down? Does the SAM represent the realistic addressable segment within the company's go-to-market reach? Cross-reference with industry reports and comparable company data.
Map the Competitive Landscape
HealthTech investors have seen multiple generations of competition in this category. Key comparables: Omada Health (IPO target, $1B+ valuation), Livongo / Teladoc (Acquired by Teladoc for $18.5B), Hims & Hers (IPO via SPAC 2021, $1.6B). Ask explicitly about differentiation from each — vague answers signal incomplete competitive awareness.
Conduct Regulatory & Compliance Review
HealthTech startups face specific regulatory risks: FDA 510(k) or PMA: medical device and diagnostic claims require pre-market review; HIPAA: PHI handling requires BAAs, security officer, breach notification protocol; Stark Law and Anti-Kickback Statute: referral and compensation arrangements in healthcare; State telehealth regulations: licensing requirements vary by state for clinical services. Verify compliance posture before advancing to term sheet.
Synthesize and Assign Investment Verdict
Combine all findings into a structured verdict: INVEST (clear thesis, strong team, de-risked execution), DIG DEEPER (promising but unresolved questions), or PASS (fundamental flaws in team, market, or traction). DDR automates this synthesis and assigns a score from 1–10.
What Series A Investors Specifically Look For in HealthTech
- $1M+ ARR or strong path within 12 months
- Proven repeatable go-to-market motion
- Net Revenue Retention >100% (expansion > churn)
- Gross margins indicating sustainable unit economics
- Management team capable of scaling to $10M ARR
- Clear competitive differentiation and moat building
Series A Red Flags (Stage-Specific)
- ARR below $500K without exceptional growth rate (>300% YoY)
- Net Revenue Retention below 90%
- No VP of Sales or equivalent GTM leader
- Customer concentration: top 3 customers >50% of ARR
- Gross margin below 60% for software
HealthTech Due Diligence — All Guides
Screen Any HealthTech Startup in 5 Minutes
Upload a pitch deck PDF and DDR automatically runs this full due diligence framework — 13 OSINT sources, founder verification, all sector-specific red flags, comparable company analysis, and INVEST/PASS verdict.
GET YOUR FREE SCAN →